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Abstract
Background: The prognosis for patients with cervical or endometrial cancer has improved over the last decades.
Thus, reducing therapy-related toxicity and impact on quality of life have become more and more important. With
the development of new radiotherapy techniques like IMRT (Intensity-modulated radiotherapy) the incidence of
acute and chronic toxicities has already been reduced. Nevertheless, rates of complications requiring medical treatment
range from 0.7–8% according to literature. 7.7% of patients develop severe complications after 5 years with an increasing
risk for complications of 0.3%/year. Particularly, the volume of the small and large bowel receiving low doses (15 Gy) has
been shown to be a predictive factor for the development of higher bowel toxicity. With the introduction of proton
therapy into clinical practice, there are new opportunities for optimization of organ at risk-sparing thus possibly reducing
toxicity.
Methods/design: The APROVE study is a prospective single-center one-arm phase-II-study. Patients with cervical or
endometrial cancer after surgical resection who have an indication for postoperative pelvic radiotherapy will be treated
with proton therapy instead of the commonly used photon radiation. A total of 25 patients will be included in this trial.
Patients will receive a dose of 45–50.4 GyE in 1.8 GyE fractions 5–6 times per week using active raster-scanning pencil
beam proton radiation. Platinum-based chemotherapy can be administered if indicated. For treatment planning, rectum,
sigma, large and small bowel, bladder and femoral heads are defined as organs at risk. The CTV is defined according to
the RTOG consensus guidelines.
Discussion: The primary endpoint of the study is the evaluation of safety and treatment tolerability of pelvic radiation
using protons defined as the lack of any CTC AE Grade 3 or 4 toxicity. Secondary endpoints are clinical symptoms and
toxicity, quality of life and progression-free survival. The aim is to explore the potential of proton therapy as a new
method for adjuvant pelvic radiotherapy to decrease the dose to the bowel, rectum and bladder thus reducing acute
and chronic toxicity and improving quality of life.
Trial registration: Registered at https://clinicaltrials.gov, ClinicalTrials.gov Identifier: NCT03184350, registered 09 June 2017,
enrolment of the first participant 19 June 2017.
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Background
Cervical cancer was once one of the most common causes
of cancer death for women. With the implementation of
regular screenings including Pap smear rates of cervical
cancer have fallen by 75% in the United States [1]. Now-
adays, cervical cancer contributes nearly 8% of all cancers
in women worldwide [2]. The American Cancer Society
estimates about 12,820 new cases of invasive cervical
cancer for 2017 [3]. Treatment of cervical cancer depends
very much on stage at time of diagnosis. Early stages are
mostly treated with surgery, whereas patients with FIGO
stage IIb or higher should be treated with definitive
radiochemotherapy. There are also cases where postopera-
tive radiotherapy is indicated to reduce the risk of tumor
recurrence [4, 5]. Risk factors for local recurrence are posi-
tive resection margins, positive lymphonodal status, >1/3
stromal invasion, capillary lymphatic space involvement,
and large clinical tumor diameter. In these cases, postoper-
ative radiotherapy can improve local-recurrence-free sur-
vival from 79 to 88% [5], however resulting in higher
toxicity rates than after surgery alone. Further studies
showed that simultaneous radiochemotherapy is superior
to radiation alone both in the adjuvant [6] and definitive
setting [7]. For example, Morris et al. could show improved
progression-free survival (80% vs. 63%) as well as overall
survival (81% vs. 71%) after combined platinum-based ra-
diochemotherapy compared to radiotherapy alone [8].
Endometrial cancer contributes nearly 5% of all cancers
in women worldwide [2]. In Europe and the United States,
it is the most common cancer of the female reproductive
organs. The American Cancer Society estimates about
61,380 new cases of endometrial cancer for 2017 [3]. Most
patients with endometrial cancer are diagnosed in an early
stage resulting in a low cancer specific mortality. Primary
treatment consists of radical surgery. The prognosis of pa-
tients with endometrial cancer depends very much on
tumor stage, grading, histology, depth of myometrial inva-
sion, capillary lymphatic space involvement and age. All pa-
tients with clear-cell or serous adenocarcinoma histology
should receive postoperative percutaneous pelvic radiother-
apy. But also patients with endometroid adenocarcinoma
FIGO stage Ib or higher and presence of risk factors should
receive postoperative radiotherapy [9–11].
Therapy-associated toxicity is the limitating factor for ad-
juvant pelvic radiotherapy. Recurrence of the vaginal cuff is
the most common site of locoregional recurrence for pa-
tients with endometrial cancer. With the use of endovaginal
brachytherapy, sufficiently high doses for a good local con-
trol can be achieved with better sparing of organs at risk
than with external beam radiotherapy alone [11]. New tech-
nical developments in the field of radiotherapy like IMRT
(intensity-modulated radiotherapy), VMAT (volumetric arc
therapy) and Tomotherapy have resulted in better sparing
of organs at risk (OARs) like rectum, bowel and bladder
thus reducing toxicity of pelvic radiotherapy. Nevertheless,
rates of complications requiring medical treatment range
from 0.7–8% according to literature [12–15]. Especially
chronic side effects have a high impact on patients’ quality
of life. In a trial with 1784 patients receiving definitive
radiotherapy for FIGO stage Ib cervical cancer, 7.7% devel-
oped severe complications after 5 years. The risk for devel-
oping complications increased for 0.3% per year resulting
in an actuarial 20-year-complication rate of 14%. Side ef-
fects most commonly consist of gastro-intestinal/gastro-
urogenital symptoms like proctitic symptoms, bleeding, fis-
tula, ulcers, hematuria or vaginal ulcers and fistulas [16].
The rate of toxicities correlates with dose per fraction, cu-
mulative dose as well as the volume of the organ at risk af-
fected by radiotherapy. A recent study by Chopra et al.
showed that particularly the extent of the bowel being ex-
posed to low doses is a crucial factor for the development
of chronic gastrointestinal toxicities [17]. The volume of
the bowel receiving less than 15 Gy could be identified as
an independent predictive factor for the development of >
grade 3 chronic intestinal toxicities. The volume of the
small bowel and large bowel receiving 15 Gy or less should
be restricted to <257cm3 and <250cm3, respectively, to
avoid late side effects [17].
In the last decade, the use of particles for radiation of
certain tumors has found its way into clinical practice.
Proton therapy with its characteristic Bragg peak allows for
a more precise radiation with better sparing of OARs thus
possibly reducing radiation related toxicities. This facilitates
dose escalation, particularly in patients receiving combined-
modality therapy, for which toxicity is enhanced. A plan-
ning study from 2012 could demonstrate that the use of
passive scattering proton therapy (PSPT) or intensity-
modulated proton therapy (IMPT) resulted in a statistically
significant decrease in dose to the small and large bowel
and kidneys, while maintaining excellent planning target
volume coverage [18]. Lin et al. published a study in 2016
of 11 patients with post-hysterectomy gynecologic cancer
who received pencil beam scanning proton radiation
therapy (PBS) to the whole pelvis. One patient (9%) devel-
oped grade 3 acute gastrointestinal toxicity, no patient
developed ≥ grade 3 genitourinary toxicity. The volume of
pelvic bone marrow, bladder, and small bowel receiving 10
to 30 Gy was significantly lower with PBS than with IMRT
with good coverage of the target volume [19].
Previous work of our group included plan comparisons
of IMRT and PBS proton therapy plans based on CT-scans
obtained for radiation treatment planning of patients with
cervical or endometrial cancer. It could be shown that with
the use of active raster scanning PBS proton radiation the
V15 of the bowel could be reduced effectively compared to
the IMRT plans (unpublished data).
The aim of this prospective study is to evaluate safety and
treatment tolerability of pelvic radiation using protons and
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to explore if reduced dose to the OARs results in clinically
apparent reduced side effects and mitigates the influence of
pelvic radiation on quality of life. All in all, we aim to assess
the potential of proton therapy as a new method for adju-
vant pelvic radiotherapy to decrease the dose to the bowel,
rectum and bladder thus reducing acute and chronic
toxicity and improving quality of life.
Methods/design
Study design
The study is designed as a prospective single-center one-
arm phase-II-trial evaluating the clinical feasibility and tox-
icity of postoperative pelvic radiation using proton therapy.
Patients fulfilling the inclusion criteria will be treated with
active raster scanning proton radiation up to total doses of
45.0–50.4 GyE in 1.8 GyE single dose fractions. 25 patients
are planned to be enrolled in a time period of 2 years.
Study objectives
The primary objective of the trial is the assessment of
safety and treatment tolerability defined as the lack of any
CTC AE ≥ grade 3 gastrointestinal or urogenital toxicity
or premature treatment abortion.
Secondary endpoints are clinical symptoms and toxicity
according to the CTC AE version 4.0. criteria, quality of
life assessed with the EORTC-QLQ30/−EN24/−CX24
questionnaires and progression-free survival.
Trial organization and coordination
The APROVE study has been designed by the study initia-
tors at the Department of Radiation Oncology in
cooperation with the Institute of Medical Biometry and In-
formatics at the University Hospital Heidelberg. The study
is carried out by the Department of Radiation Oncology in
cooperation with the Heidelberg Ion beam Therapy-center.
Statistical analysis is performed by the Institute of Medical
Biometry and Informatics at the University of Heidelberg.
The overall coordination is performed by the Department
of Radiation Oncology at University Hospital Heidelberg.
This department is also responsible for the overall trial
management, database management, quality assurance in-
cluding monitoring and reporting.
Investigators
The study investigators are experienced radiation oncol-
ogists specialized in the treatment of patients with gyne-
cologic malignancies. Patients will be recruited and
treated by the physicians of the Department of Radiation
Oncology of the University Hospital Heidelberg.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Heidelberg, Germany
(Nr: S-155/2016) and by an independent expert group of
the German Society for Radio-oncology (DEGRO). This
study complies with the Helsinki Declaration in its
recent German version, the principles of Good Clinical
Practice (GCP) and the Federal Data Protection Act.
The trial will also be carried out in keeping with local
legal and regulatory requirements. The medical secrecy
and the Federal Data Protection Act will be followed.
The ClinicalTrials.gov Identifier is NCT03184350.
Data handling, storage and archiving of data
All findings including clinical and laboratory data will
be documented by the investigator or an authorized
member of the study team in the subject’s medical
record and in the case report form (CRF). The data
will be stored and archived according to the §13 of
the German GCP-Regulation and §28 c of the German
X-Ray Regulation (StrlSchV) for at least 30 years after the
trial termination.
Patient selection
Inclusion criteria according to the protocol are:
 Histologically confirmed cervical or endometrial
cancer
 Indication for postoperative radiotherapy
 Karnofsky Index ≥70
 Age between 18 and 80 years
 Written informed consent
Exclusion criteria are the following:
 patients refusal or incapability of informed consent
 implanted active medical devices lacking approval
for ion beam radiation
 metallic implants in the radiation field, e.g. hip
prostheses
 prior pelvic irradiation
 participation in another clinical trial which might
influence the results of the APROVE trial
Simultaneous chemotherapy is NOTan exclusion criterium.
Sample size calculation and statistical analysis
The APROVE trial is a prospective single-center one-arm
phase-II-study. Primary endpoint is the evaluation of safety
and treatment tolerability of pelvic radiation using proton
beam radiotherapy. 25 patients will be included in the
study. Sample size calculation was performed to demon-
strate a treatment tolerability rate higher than 80% with a
power of 1-β = 0.90 using a binomial test at a one-sided sig-
nificance level of α = 0.1 under the assumption of an actual
treatment tolerability rate of 0.96. The primary analysis in-
cludes all enrolled patients. In addition, a per-protocol ana-
lysis will be performed. For the primary endpoint, a point
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estimate for the tolerability rate will be calculated alongside
a one-sided 90- and 95%- confidence interval. Methods of
descriptive data analysis will be used to evaluate the sec-
ondary endpoints and safety data. This includes calculation
of appropriate measures of the empirical distribution and
graphical display of the results.
Investigation schedule
Indication
The oncological treatment concept for each patient is based
on interdisciplinary assessment following approved standard
therapies and guidelines. The adjuvant treatment is defined
after surgery and complete staging including thoraco-
abdominal CT scan and pelvic MRI scan. This allows for
histologically confirmed diagnosis, classification and staging.
According to institutional policies the following patients
receive whole pelvic radiotherapy:
Cervical cancer patients: All patients with FIGO stage ≥
IIb, N+ or positive resection margins and no possibility of
further resection. Furthermore, patients with FIGO stage
< IIb and a combination of risk factors like lymphangiosis
carcinomatosa (L1), deep stromal invasion, tumor size
>4 cm (according to the Sedlis criteria [5] and the german
S3-guidelines).
Endometrial cancer patients: All patients with serous, clear
cell or undifferentiated histology and all patients with endo-
metroid, mucinous or adenosquamous carcinomas FIGO
stage ≥ III. Furthermore, patients with FIGO stage I/II ac-
cording to the ESMO-ESGO-ESTRO Consensus Conference
on Endometrial Cancer [20] taking into account lymphade-
nectomy and risk factors such as lymphovascular invasion,
depth of myometrial invasion, grading and patient age (ac-
cording to the risk classification developed by the PORTEC
and GOG groups).
In general, every patient with an indication for percutan-
eous pelvic radiotherapy also receives a high dose rate
(HDR)-vaginal brachytherapy (VBT)-boost.
Radiotherapy-planning
In order to ensure accurate reproducibility of patient
positioning, the patient is immobilized using a ProSTEP
(ITV, Innsbruck, Austria). CT scans are obtained in the
immobilization device in 3 mm-slices. Target volumes and
organs at risk are defined using Siemens TPS Version,
Syngo RT Planning VC13A for contouring and dose
calculation. The target volume is defined according to
the RTOG consensus guidelines [21]. A margin of
5 mm and 7 mm in beam direction will be used to
create the PTV (planning target volume) according to
internal standards. OARs are small and large bowel,
sigma, posterior wall of the rectum, bladder and fem-
oral heads. Tolerated maximum doses to OARs must
not exceed the TD5/5 for each organ [22].
Radiation therapy
After validation of the treatment plan by the radiation
oncologist and the physicist in charge, treatment is applied in
daily fractions of 5–6 × 1.8 Gy per week to a total dose of
45–50.4 Gy using active raster scanning proton radiation.
Total treatment duration hence is 4–5 weeks. Isocenter and
patient positioning are checked daily by on-line orthogonal
x-ray-imaging and by regularly performed off-line positioning
control CT scans. Treatment time is expected to be about
35–45 min. Treatment will be carried out on an out-patient
basis unless the patient’s condition requires hospital
admission.
HDR-VBT-boost is applied the week after finishing per-
cutaneous proton radiation to minimize the confounder of
additional acute bladder and rectal toxicities. HDR-VBT-
boost is delivered to the upper two thirds of the vagina by
using a vaginal cylinder. Single fractions of 5 Gy to the vagi-
nal mucosa at 5 mm depth are delivered (two fractions, cu-
mulative dose 10 Gy), CT-based treatment planning is used
for 3-D-optimization.
Monitoring during treatment/adverse events
Patients are evaluated weekly during radiotherapy.
Radiotherapy-related toxicities are assessed using the
National Cancer Institute (NCI) Common Toxicity Criteria
(CTC) version 4.0. Toxicity will be evaluated pre-treatment,
weekly during radiation therapy and at follow-up.
Unacceptable toxicity for every individual patient is defined
as unpredictable or irreversible ≥ grade 4 toxicity. Unaccept-
able toxicity resulting in premature termination of the whole
trial is defined as any grade 5 toxicity, two consecutive grade
4 toxicities or 5 consecutive grade 3 toxicities.
Expectable possible acute toxicities (up to 3 months post
radiation therapy) are fatigue, loss of appetite, weight loss,
skin toxicity, nausea, vomiting, irritable bowel syndrome,
diarrhea, proctitis, dysuria, hematological toxicity. All acute
toxicities should resolve within a few weeks after radiation
therapy. Late side effects are rare and are defined as symp-
toms appearing at least 3 months post radiation. These could
include chronic diarrhea, malabsorptive syndrome, chronic
bladder inflammation, enterocolitis, strictures, fibroses, ul-
cers, chronic bleeding. Very rare symptoms are fistulation,
perforation, peritonitis, intestinal necrosis or ileus necessitat-
ing surgical intervention.
Follow up
Patients are included into standard gynecology follow-up
program. Additionally, regular study visits at 6 weeks,
3 months, 6 months, 9 months, 12 months, 18 months and
24 months post treatment are intended. Each visit includes
update of medical history, assessment of symptoms and
treatment toxicity. In addition, pelvic MRI-scans are per-
formed 3, 6, 9, 12, 18, 24 months post treatment and quality
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of life is assessed 6 weeks, 3, 6, 12 and 24 months post treat-
ment (Fig. 1).
Duration of the study
The primary objective of the study is to prove good
treatment tolerability of pelvic radiation using proton
beam radiotherapy, defined as the non-occurrence of
CTC grade 3 gastrointestinal or urogenital toxicities dur-
ing radiotherapy and up to 3 months after its comple-
tion. To assess the primary endpoint, the final study visit
will be 3 months after the last patient completed the
radiotherapy. The study ends 2 years after the last pa-
tient was treated. Recruitment of the patients is planned
over a time period of 2 years.
Discussion
The prognosis for patients with cervical or endometrial
cancer has improved dramatically over the last decades.
This is mostly due to more intensive screening pro-
grams, better prevention but also improved therapeutic
options. Thus, developing new therapeutic techniques in
order to reduce therapy-associated long-term toxicities
and to improve quality of life of cancer patients has be-
come more and more important. With the development
of IMRT the incidence of acute and chronic toxicities
could already be reduced. Nevertheless, therapy-
associated complications requiring medical treatment
are a relevant issue: 7.7% of patients develop severe
complications after 5 years with an increasing risk for
complications of 0.3%/year [16]. The introduction of
proton therapy into clinical practice over the last few
years offers one more opportunity for better sparing of
organs at risk. A recent study from Philadelphia could
already show that also for gynecologic malignancies the
use of pelvic proton therapy results in lower doses to
OARs with simultaneously good coverage of the target
volume [19]. This resulted in a low rate of therapy-
associated side effects with only one patient developing
acute gastrointestinal toxicity grade 3. This study con-
sisted of only 11 patients. Further studies with bigger
collectives are necessary to verify these finding and to
evaluate long-term side effects and the impact on quality
of life of patients treated with proton therapy for gyne-
cologic malignancies.
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